Navigation Links
Bio-Matrix Scientific Group, Inc. Gets Updated Stock Recommendation By KonLin Investment Letter
Date:3/23/2009

SAN DIEGO, March 23 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN), a San Diego-based biotechnology company, today announced that it has received an updated stock buy recommendation from the KonLin Letter, a New York-based investment newsletter (www.konlin.com) published by KonLin Research & Analysis. The investment letter cited BMSN's recent Human Cell Tissue (HCT) Specimen Processing, Testing and Cryogenic Storage contract with NeoCells, Inc. and AdultCells, Inc. as the primary reason for the updated stock buy recommendation.

According to Konrad Kuhn, editor and publisher of the KonLin Letter, the recent BMSN contracts have, "the potential to generate substantial first year as well as ongoing revenues." Kuhn pointed out that BMSN is about to dramatically change as it turns the corner to full commercialization. Kuhn reported in his investment newsletter that, "Winning a major contract demonstrates the substantial progress recently made by BMSN towards generating revenue. The contract's potential to generate revenue for BMSN can positively impact business, expansion and share price, as revenues begin to replace outside investment as the primary source of operating capital."

Kuhn stated that his investment newsletter recommended BMSN in January 2007, "as one of our featured stocks of the year, which rewarded investors with 243% to 550% gains. We would reenter/add/buy once again for an anticipated 1st target of $1.50-$1.70. In the coming years, the focus of research will be stem cell-based cell therapy in a combination of cell and gene therapy techniques. Ultimate target (for BMSN's stock price) is $3.00-$4.00."

Bio-Matrix Scientific Group, Inc. (OTC Bulletin Board: BMSN) is a publicly-traded biotechnology research and development company based in San Diego, Ca. with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, asceptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories. The company also commercializes medical devices and monitoring systems for the growing worldwide stem cell research market.

Disclaimer:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Bio-Matrix Scientific Group, Inc. Highlighted in LifeSciencesWorld.com Special Report; Stem Cell Market Projected to Exceed $8 Billion Worldwide by 2016
2. Bio-Matrix Scientific Group Featured as Stock Pick in Oakleys Column on WallStreetCorner.com
3. Bio-Matrix Scientific Group Announces New Hires to Management Team
4. Joseph Loscalzo, M.D., PhD. to Join N30 Pharma Board and Chair Scientific Advisory Board
5. Boston Scientific Launches New Coronary Imaging Catheter
6. Milestone Scientific to Report 2008 Year-End Results on Tuesday, March 17, 2009
7. Moodys Raises Boston Scientifics Rating Outlook to Stable
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Irvine Scientific Launches IS CHO-CD XP(TM)
10. Boston Scientific Resolves Outstanding Litigation Matter, Finalizes Goodwill Impairment Charge
11. Edmond Scientific Company Spotlight on the Executive:
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... ... AMRI, a global contract research, development and manufacturing organization ... quality of life, will now be offering its impurity solutions as a stand-alone ... for all new drug products, including the finalization of ICH M7 earlier this ...
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building ... corporate rebranding initiative announced today. The bold new look is part of a ... company moves into a significant growth period. , It will also expand its service ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ... appointment of independent Directors Mr. Robin D. Richards ... Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive ... their guidance and benefiting from their considerable expertise as we ...
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
Breaking Biology News(10 mins):